CVRx, Inc. (CVRX)
Largest Insider Buys in Sector
CVRX Stock Price History Chart
CVRX Stock Performance
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated …
Insider Activity of CVRx, Inc.
Over the last 12 months, insiders at CVRx, Inc. have bought $322,508 and sold $151,890 worth of CVRx, Inc. stock.
On average, over the past 5 years, insiders at CVRx, Inc. have bought $15.87M and sold $119,052 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hykes Kevin (PRES & CEO) — $250,767. SLATTERY JOSEPH P (director) — $143,482.
The last purchase of 3,000 shares for transaction amount of $24,300 was made by SLATTERY JOSEPH P (director) on 2024‑08‑15.
List of Insider Buy and Sell Transactions, CVRx, Inc.
| 2024-08-15 | director | 3,000 0.0133% | $8.10 | $24,300 | 0.00% | |||
| 2024-08-08 | director | 3,000 0.0134% | $8.24 | $24,716 | +1.65% | |||
| 2024-08-06 | director | 2,500 0.0115% | $9.09 | $22,725 | -5.14% | |||
| 2024-08-05 | PRES & CEO | 30,000 0.1373% | $8.36 | $250,767 | +2.01% | |||
| 2024-02-20 | Sale | CHIEF MKTG & STRAT OFFICER | 2,545 0.0121% | $21.91 | $55,748 | -56.74% | ||
| 2024-02-16 | Sale | 10 percent owner | 3,725 0.0203% | $25.81 | $96,142 | -57.73% | ||
| 2023-08-03 | Sale | CHIEF MKTG & STRAT OFFICER | 628 0.0031% | $18.55 | $11,652 | -4.31% | ||
| 2023-07-31 | Sale | CHIEF MKTG & STRAT OFFICER | 1,122 0.0056% | $17.49 | $19,629 | -2.90% | ||
| 2022-11-28 | Sale | CHIEF MKTG & STRAT OFFICER | 4,600 0.023% | $11.94 | $54,931 | +27.16% | ||
| 2022-05-24 | 8,070 0.0378% | $5.05 | $40,752 | +81.37% | ||||
| 2022-05-19 | 10,976 0.0534% | $5.04 | $55,297 | +87.72% | ||||
| 2022-05-03 | 3,992 0.0194% | $6.00 | $23,936 | +54.82% | ||||
| 2022-04-28 | 41,988 0.1855% | $5.97 | $250,673 | +40.06% | ||||
| 2022-02-28 | director | 600 0.003% | $9.03 | $5,420 | -5.13% | |||
| 2022-02-24 | director | 3,400 0.0158% | $8.24 | $28,010 | -3.59% | |||
| 2022-02-23 | director | 38,200 0.1877% | $8.04 | $307,143 | +4.13% | |||
| 2022-02-22 | director | 40,008 0.1932% | $7.94 | $317,660 | +3.23% | |||
| 2022-02-18 | director | 26,659 0.1289% | $7.92 | $211,227 | +3.43% | |||
| 2021-11-19 | director | 600 0.006% | $13.69 | $8,213 | -38.88% | |||
| 2021-11-18 | director | 1,750 0.0172% | $14.63 | $25,607 | -43.58% |
Insider Historical Profitability
| SLATTERY JOSEPH P | director | 30645 0.1263% | $15.26 | 3 | 0 | |
| Hykes Kevin | PRES & CEO | 30000 0.1236% | $15.26 | 1 | 0 | |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10 percent owner | 2026083 8.3503% | $15.26 | 1 | 0 | <0.0001% |
| NEA PARTNERS 10 L P | 10 percent owner | 2026083 8.3503% | $15.26 | 1 | 0 | <0.0001% |
| Pardo Geoffrey B | director | 1829022 7.5381% | $15.26 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Johnson & Johnson | $74.72M | 19 | 4.1M | +17.39% | +$11.07M | 1.75 | |
| Nea Management Company Llc | $43.17M | 10.98 | 2.37M | 0% | +$0 | 0.2 | |
| BlackRock | $13.93M | 3.54 | 764,999 | -4.78% | -$699,901.31 | <0.0001 | |
| Balyasny Asset Management Llc | $11.26M | 2.86 | 618,530 | +51.97% | +$3.85M | 0.03 | |
| The Vanguard Group | $10.82M | 2.75 | 594,312 | +5.64% | +$577,621.17 | <0.0001 |